Equities Analysts Issue Forecasts for XBIO FY2026 Earnings

Xenetic Biosciences Inc (NASDAQ:XBIO) – Research analysts at HC Wainwright issued their FY2026 earnings per share estimates for Xenetic Biosciences in a research report issued on Monday, November 11th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.64) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.75) EPS.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The company had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.75 million.

Xenetic Biosciences Stock Up 0.8 %

Shares of Xenetic Biosciences stock opened at $3.69 on Thursday. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20. The company has a market capitalization of $5.68 million, a P/E ratio of -1.39 and a beta of 2.25. The company has a 50 day moving average of $3.89 and a 200 day moving average of $3.93.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.